



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Hyderabad, February 06th, 2019

To
The General Manager,
Listing Department,
Bombay Stock Exchange Limited,
1st Floor, New Trading Wing,
Rotunda Building, P.J. Towers,
Dalal Street Fort,
Mumbai- 400 001.

Dear Sir/Ma'am,

Sub: Financial Results for the quarter ended 31st December, 2018 – Regulation 33 (3) (a).


Ref: Company Scrip Code: 524711


With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its meeting held on Wednesday, 06th February, 2018 at 04.00 P.M. at the Corporate office of the Company, interalia, considered and approved the un-audited Financial Results for the quarter ended 31st December, 2018.

Copy of Un-audited Financial Results for the quarter ended 31st December, 2018, along with copy of Limited Review Report is enclosed herewith.

Kindly take the same on record and acknowledge the receipt of the same.

Thanking You,
for Vista Pharmaceuticals Limited


M. H. Rao
Director
DIN: 00129311





Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

VISTA PHARMACEUTICALS LIMITED

CIN:L24239TG1991PLC012264

Statement of Unaudited Financial Results for the Quarter ended 31st December,2018 (in Rs Lakhs)

S.No	Particulars	Quarter ended			Year to Date Nine Months ended on		Financial Year ended
		3 Months Ended	Preceding 3 Months Ended	Corresponding 3 Months ended in the Previous Year	Year To Date figures for the current Period ended	Year To Date figures for the Previous Period ended	Previous Year Ended
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Income						
	a. Revenue from operations	701.45	588.00	711.59	1889.11	2110.93	2891.78
	b. Other income	173.64	62.66	0.00	291.38	70.07	39.68
2	Total Income (a+b)	875.09	650.66	711.59	2180.49	2181.00	2931.46
3	Expenses						
	a) Cost of Material Consumed	726.18	383.70	370.31	1498.90	1181.00	1596.27
	b) Change in Inventories	-	-	-	-	-	-
	c) Employee benefits expense	32.66	37.17	26.68	100.33	71.42	105.40
	d) Finance costs	42.50	40.71	38.18	126.95	117.30	157.49
	e) Depreciation and amortization expense	34.59	34.59	56.04	102.16	111.07	133.56
	f) Other expenses	25.73	108.17	148.49	253.93	481.90	656.04
	Total Expenses	861.67	604.34	639.70	2,082.28	1,962.69	2,648.77
4	Profit before tax (2-3)	13.42	46.33	71.89	98.21	218.31	282.69
5	Tax expense						
	(1) Current tax	2.76	6.76	14.66	20.22	44.51	57.64
	(2) Deferred tax	1.75	30.33	(2.22)	49.33	12.81	6.41
6	Net Profit for the Period (4-5)	8.91	9.24	59.45	28.66	160.99	218.65
7	Other comprehensive income (OCI)						
	(a) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Tax on items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive income	-	-	-	-	-	-
8	Total Comprehensive income (6+7)	8.91	9.24	59.45	28.66	160.99	218.65
	Earnings per equity share (Face value of Rs.10/- each)						
	(1) Basic	0.03	0.03	0.21	0.10	0.56	0.76
	(2) Diluted	0.03	0.03	0.21	0.10	0.56	0.73
	Paid-up equity share capital(Face Value of Rs.2/- each)	599.70	582.94	572.94	599.70	572.94	582.94


Notes:

1.The above Financial results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 06.02.2019.

2.The Standalone Financial results for the quarter and nine months ended 31.12.2018 are reviewed by the Statutory Auditors of the Company as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3.The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made.

4.During the quarter 8,37,720 warrants were converted in to 8,37,820 equity shares for Rs.50/- per share (face value-Rs.2/- per share and premium Rs.48/- per share.



MAHESH, VIRENDER & SRIRAM

Chartered Accountants

6-3-788/36 & 37A, Durganagar Colony, Ameerpet, Hyderabad-500 016

Phone 040-23401738

E-mail : mvshyd@yahoo.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF VISTA PHARMACEUTICALS LIMITED


We have reviewed the accompanying Statement of Unaudited Financial Results of VISTA PHARMACEUTICALS LIMITED ("the Company"), for the quarter ended December 31, 2018 ("the Statement"), and the year to date results for the period from 1 April 2018 to 31 December 2018, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Mahesh Virender & Sriram
Chartered Accountants
(Firm's Registration No. 001939S)



R.V. Chalam
R.V. Chalam
Partner
M. No: 21423

Place: Hyderabad
Date: 06/02/2019